Plné znění - 2/2008 Sb. m. s.

Ministerstvo zahraničních xxxx xxxxxxx, xx xxx 16. xxxxxxxxx 2007 bylo xxxxxxxxxx xxxxxxxxx XXXXXX, xxxxxxxxxxx Xxxxxxxxxxx xxxxxx xxxxx xxxxxxx xx xxxxxx¹⁾, xxxxxxxx xxxxxxxxx xxxxxx xxxxx Přílohy I - Xxxxxxx xxxxxxxxxx xxxxx x metod xxxxxxx.

Xxxxxxx X xxxxxxxxx x platnost v xxxxxxx x článkem 34 xxxx. 3 Xxxxxx xxx 1. ledna 2008 x tímto xxxx xxxxxxxxx v xxxxxxxx x xxx Xxxxxx republiku. Xxxx xxxxxx Přílohy X x platnost xxxxxxxx xxxxxx Xxxxxxx X Xxxxxxxxxxx xxxxxx proti xxxxxxx xx xxxxxx xx xxxxx xxx xxx 2007, xxxxxxxxx xxx č. 59/2007 Xx. m. s.

Xxxxxxxx xxxxx Xxxxxxx X a xxxx xxxxxxx do xxxxxxx xxxxxx se vyhlašují xxxxxxxx.

X1. XXXXXXXXXX LÁTKY

Xxxxxxxxxx xxxxx xxxx xxxxxxxx.

1. ANDROGENNÍ XXXXXXXXXX STEROIDY (XXX):

x. Xxxxxxxx * XXX, xxxxxxxxxx:

1-xxxxxxxxxxxxx (5α-xxxxxxx-1-xx-3β,17β-xxxx); 1-xxxxxxxxxxxxx (5α-xxxxxxx-1-xx-3,17-xxxx); xxxxxxxxx (19-xxxxxxxxxxxxxxxx); xxxxxxxxxx; xxxxxxxx; boldion (xxxxxxxx-1,4-xxxx-3,17-xxxx); xxxxxxx (17α-ethynyl-17β-hydroxyandrost-4-eno[2,3-d]isoxazol); dehydrochlormethyltestosteron (4-xxxxxx-17β-xxxxxxx-17α-xxxxxxxxxxxxx-1,4-xxxx-3-xx); desoxymethyltestosteron (17α-metyl-5α-androst-2-en-17β-ol); xxxxxxxxxxx; ethylestrenol (19-xxx-17α-xxxxx-4-xx-17-xx); xxxxxxxxxxxxxx; formebolon; xxxxxxxxx (17β-xxxxxxx-17α-xxxxx-5α-xxxxxxxxxx[2,3-x]-xxxxxxx); gestrinon; 4-xxxxxxxxxxxxxxxxxx (4,17β-xxxxxxxxxxxxxxxx-4-xx-3-xx); xxxxxxxxxx; xxxxxxxxx; xxxxxxxxxx; mesterolon; xxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxxxxx-1,4-xxxx-3-xx); xxxxxxxxx; xxxxxxxxxxx; xxxxxxxxxx (2α, 17α-dimetyl-5α-androstan-3-on-17β-ol); xxxxxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxx-4,9-xxxx-3-xx); methyl-1-testosteron (17β-xxxxxxx-17α-xxxxx-5α-xxxxxxx-1-xx-3-xx); xxxxxxxxxxxxxxxxxxxx (17β-hydroxy-17α-metylestr-4-en-3-on); xxxxxxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxx-4,9,11-xxxxx-3-xx); methyltestosteron; xxxxxxxxx; xxxxxxxxx; 19-xxxxxxxxxxxxxxxx (xxxx-4-xx-3,17-xxxx); xxxxxxxxxx; xxxxxxxxxxxxxx; xxxxxxxxxxxx; xxxxxxxx; oxandrolon; xxxxxxxxxxx; xxxxxxxxxx; xxxxxxxxxxx ([3,2-x]xxxxxxx-5α-xxxxxxxxxxxxxx-17β-xxxxxxxxxxxxxxxxx); xxxxxxxxx; stanozolol; xxxxxxxxx; 1-xxxxxxxxxxx (17β-xxxxxxx-5α-xxxxxxx-1-xx-3-xx); xxxxxxxxxxxxxxxxxxx (18α-homo-pregna-4,9,11-trien-17β-ol-3-on); xxxxxxxxx x xxxxx xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx podobnými xxxxxxxxxxxx xxxxxx.

x. Xxxxxxxxx ** AAS:

Xxxxxxxxxxxxx (xxxxxxx-5-xx-3β,17β-xxxx), androstendion (xxxxxxx-4-xx-3,17-xxxx), xxxxxxxxxxxxxxxxxx, xxxxxxxxx (xxxxxxxxxxxxxxxxxxxxx, XXXX), testosteron x xxxxxxxxxxx xxxxxxxxxx x xxxxxxx:

5α-androstan-3α,17α-diol androst-5-en-3β,17α-diol

5α-xxxxxxxxx-3α,17β-xxxx 4-xxxxxxxxxxxxx (xxxxxxx-4-xx-3β,17β-xxxx)

5α-xxxxxxxxx-3β,17α-xxxx 5-xxxxxxxxxxxxx (xxxxxxx-5-xx-3,17-xxxx)

5α-androstan-3β,17β-diol epi-dihydrotestosteron

androst-4-en-3α,17α-diol 3α-hydroxy-5αandrostan-17-on

xxxxxxx-4-xx-3α,17β-xxxx 3β-xxxxxxx-5αxxxxxxxxx-17-xx

xxxxxxx-5-xx-3β,17α-xxxx 19-xxxxxxxxxxxxxx

androst-5-en-3α,17α-diol 19-noretiocholanolon

xxxxxxx-5-xx-3α,17β-xxxx

X xxxxxxxxx, xxx xxxx xxxx xxxxxxxxxx androgenní xxxxxxxxxx xxxxxxx přirozeně, xxxx xx xxx xx xx, že Xxxxxx xxxxxxxx xxxx Xxxxxxxxx xxxxx x xxxx xxxxxx pozitivní Xxxxxxxxx laboratorní xxxxx, xxxx xx xxxxxxxxxxx Xxxxxxxx xxxxx xxxx xxxxxx metabolitů nebo xxxxxxxxxxx x/xxxx když xx xxxxxxxx jiný xxxxxxxxx poměr ve Xxxxxx Xxxxxxxxx xxxxxxxx xxxxxxxxx od rozmezí xxxxxx, které xx xxxxxxxx xxxxxxxxx u xxxx xxx, že xxxxxxxxxx normální xxxxxxxxx xxxxxxxx. Xxxxxx xx xxx za xx, xx Xxxxxx obsahuje Xxxxxxxxx xxxxx v xxxxxxx xxxxxxx, xxxxx Xxxxxxxxx xxxxxxx, xx xx xxxxxxxxxxx Zakázané xxxxx xxxx xxxxxx xxxxxxxxxx xxxx xxxxxxxxxx x/xxxx příslušný xxxxx xx Vzorku Xxxxxxxxx xxxxxxxx xxxxxxxxxxxxx xxxx xxxxxxxxxxxx xxxxxx.

Bude xx mít za xx, xx Xxxxxx Xxxxxxxxx xxxxxxxx Zakázanou xxxxx a xxxxxxxxx xxxxxxx Pozitivní xxxxxxxxxxx xxxxx xx všech xxxxxxxxx a xxx xxxxxxxxx koncentraci, xxxxx xxx podle spolehlivé xxxxxxxxxx xxxxxx (xxxx. XXXX) xxxxxxxx, že xx Xxxxxxxx xxxxx xxxxxxxxxx xxxxxx. X xxxxxxx případě xxxx xxxxx provádět xxxxx xxxxxxx.

Xxxx xx xxxxxxx xxxxxxxx xxxxxxx xxxxxxxx xxxxxxxxxxx xx xxxxxxx xxxxxx, xxxxx xx xxxxxxxx xxxxxxxxx x xxxx a xxxxx xxxxxxxxxx xxxxxxxxxx xxxxxx (xxxx. IRMS) xxxxxxxxxxx xxxxxxxx xxxxx Xxxxxxxx xxxxx, xxx xxxxxxxx xxxxxx xxxxxxx Xxxxxxxx xxxxx, jako xxxx. xxxxxxxxx x xxxxxxxxxxx referenčními steroidními xxxxxxx, xxxx xxxx xxxxxxxxx xxxxxxxxx xxxxx X/X vyšší xxx xxxxx (4) ku xxxxx (1) x xxxxx xxxxxxxxxx xxxxxxxxxx xxxxxx (xxxx. XXXX) xxxxxxxxxxx xxxxxxxx xxxxx xxxxx, xxxxxxx příslušná Xxxxxxxxxxxxx organizace xxxxx xxxxxxx xxxxxxxxxx xxxxxxxx xxxxxxxxxx testů xxxx xxxxxxxxxx xxxxxxxxxx xxxxx.

Xx-xx xxxxxxxxxx takové xxxxx šetření, xxx xxxxxxxx bude xxxxxxxxxx xxxxxx xxxx neobvyklý x xx xxxx xxxxxxxxx. Xxxxx xxxxxxxxx xxxxxxx, xx xxxxxxx xxxxxxxxxx xxxxxxxxxx xxxxxx (xxxx. IRMS) xxxxxxxx xxxxx Xxxxxxxx xxxxx, xxxx xxxxx provádět xxxxx xxxxxxx, a xxxx xx xxx xx xx, xx Xxxxxx xxxxxxxx Xxxxxxxxx xxxxx. Pokud nebyla xxxxxxx xxxxxxxxxx xxxxxxxxxx xxxxxx (xxxx. IRMS) x xxxxxx x xxxxxxxxx xxxxxxxxx 3 xxxxxxxxx xxxxx, xxxx xxxxxxx xxxxxxxxxxxxxx profil Xxxxxxxxx xxx, xx xxxx příslušnou Xxxxxxxxxxxxxx xxxxxxxxxx v xxxxxxxxxxxxx 3 xxxxxxxx xxxxxxx xxxxxxxx xxx xxxxxxxxxxx xxxxxxxx. Xxxxxxxx, xxxxx xxxxxxxxxx xxxx xxxxxxxxxxxxxx xxxxxx, xxxx xxxxxx xxxx neobvyklý. Xxxxx xxxxxxxxxxxxxx xxxxxx Sportovce, xxxxxxxx xxxxxxxxxx xxxxx, xxxx xxxxxxxxxxxx xxxxxxxx, xxxx xx pak xxxxxxxxx xx Xxxxxxxxx xxxxxxxxxxx xxxxx.

X xxxxxxxx xxxxxxxx individuálních xxxxxxxxx xxxx xxx x moči xxxxxx xxxxxxx xxxxxxxx xxxxxxxxxxx xxxxxx ve xxxxxx xxxxxx xxxxxxxxxxxxx (xx/xx). Xxxxx xxxxxxxxx xxxxxx xxxxx nahlásila a xxxxxxx spolehlivé xxxxxxxxxx xxxxxx (xxxx. XXXX) xxxxxxxxxxx xxxxxxxx xxxxx Xxxxxxxx xxxxx, xxxx xxx xxxxxxxxx xxxxx xxxxxxx xxxxxxxxxx následného xxxxx (xxxxxxxxxx testů).

Xxxxx laboratoř xxxxxxxxx Xxxxxxxxx xxxxxxxxxxx nález 19-xxxxxxxxxxxxxxx, xxxx xx xx považovat xx xxxxxxx a přesvědčivý xxxxx xxxxxxxxxx původu Xxxxxxxx xxxxx. X xxxxxxx případě xxxx xxxxx provádět xxxxx xxxxxxx.

X případě, xx Sportovec nebude xxxxxxxxxxxxx při xxxxxxx xxxxxxxxx, bude xx xxx xx xx, xx Vzorek Xxxxxxxxx xxxxxxxx Xxxxxxxxx látku.

2. Xxxxxxx xxxxxxxxxx xxxxx, xxxxxxxxxx:

Xxxxxxxxxxx, xxxxxxxxxx modulátory xxxxxxxxxxxxx xxxxxxxxx (XXXX), tibolon, xxxxxxx, zilpaterol, ale xx x xxxxxxxx xxxxx xx ně.

S2. XXXXXXX X PŘÍBUZNÉ XXXXX

Následující látky x jejich xxxxxxxxxx xxxxxxx xxxx xxxxxxxx:

1. Xxxxxxxxxxxx (XXX);

2. Xxxxxxx xxxxxx (xXX), insulinu xxxxxxx xxxxxxx faktory (xxxx. XXX-1), mechanické xxxxxxx xxxxxxx (XXX);

3. Xxxxxxxxxxxxx (xxxx. XX, xXX), zakázané xxx x xxxx;

4. Xxxxxxxx;

5. Xxxxxxxxxxxxxx

x xxxxx látky x xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx.

Xxxxx Xxxxxxxxx xxxxxx prokázat, xx xxxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxxx či xxxxxxxxxxxx xxxxxx, xxxx xx xxx za xx, xx Xxxxxx xxxxxxxx Xxxxxxxxx látku (xxx xx xxxxxxx xxxx) x xxxxxxxxx, xxx koncentrace Zakázané xxxxx nebo xxxxxx xxxxxxxxxx či xxxxxxxxxx x/xxxx xxxxxxxxx poměry xx Xxxxxx Xxxxxxxxx xxxxxxx překročí xxxxxxx xxxxxxxx xxxxxxxx x xxxx xxx, že xxxxxxxxxxxx normální xxxxxxxxx xxxxxxxx.

Xxxxx xxxxxxxxx xxxxxxxxx, xx xxxxx xxxxxxxxxx xxxxxxxxxx xxxxxx, xx Zakázaná látka xx exogenního původu, xxxx se xxx xx xx, xx Xxxxxx xxxxxxxx Xxxxxxxxx xxxxx x xxxx xxxxxxx Pozitivní xxxxxxxxxxx xxxxx.

X3. XXXX-2 AGONISTÉ

Všichni xxxx-2 xxxxxxxx včetně xxxxxx X- a X-xxxxxxx xxxx xxxxxxxx.

Xxxxxxxx jsou xxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxx x xxxxxxxxxx, xxx které xx xxx xxxxxxxx xxxxx udělení xxxxxxxx xxxxxxxxxxxx xxxxxxx.

I xxxx byla udělena xxxxxxxx xxxxx terapeutické xxxxxxx, xxxx xxxxx xxxxxxxxxxx (volný plus xxxxxxxxxx) xxxxx xxx 1000 xxxxxxxxx v 1 mililitru xxxx xxxxxxxxx xx Pozitivní xxxxxxxxxxx xxxxx, xxxxx Xxxxxxxxx xxxxxxxxx, xx xxxxxxxxxx výsledek xxx xxxxxxxx terapeutickým užíváním xxxxxxxxxxx x xxxxxxxx.

X4. XXXXXXXXXXX X XXXXXXXXXX XXXXXXX

Xxxxxxxxxxx skupiny jsou xxxxxxxx:

1. Inhibitory xxxxxxxx, xxxxxxxxxx:

2. Xxxxxxxxxx xxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxx (XXXX), xxxxxxxx:

3. Xxxxxxx xxxxxxxxxxxxxx xxxxx xxxxxxxxxx:

4. Xxxxx xxxxxxxxxxxx xxxxxx xxxxxxxxxx včetně inhibitorů xxxxxxxxxx, xxx xx x xxxxxxxx xxxxx xx xx.

X5. DIURETIKA X XXXXXXX XXXXXXXXX XXXXX

Xxxxxxxxx xxxxx xxxx xxxxxxxx. Zahrnují:

Xxxxxxxxx*, xxxxxxxxxxxxxx, probenecid, xxxxxxxxxx xxxx-xxxxxxxxx (např. xxxxxxxxxx, xxxxxxxxxx), xxxxxxxxxxxxxxx (xxxx. albumin, xxxxxxx, xxxxxxxxxxxxxxxxx) x další xxxxx s podobnými xxxxxxxxxxxx xxxxxx.

Diuretika xxxxxxxx:

Xxxxxxxxxxxx, xxxxxxxx, xxxxxxxxx, furosemid, xxxxxxxxxxxx, xxxxxxxxx, kanrenon, xxxxxxxx xxxxxxxxxx, metolazon, spironolakton, xxxxxxxx (xxxx. xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxx), xxxxxxxxxx x xxxxx xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx (xxxxx xxxxxxxxxxxx, xxxxx xxxx xxxxxxxx).

* Xxxxxxxxxxxx xxxxxxx xxxx platná, xxxxx xxx Xxxxxxxxx xxxxxxxx diuretika ve xxxxxxx x prahovou xxxx xxxxxxxxxxx xxxxxxxx xxxx Xxxxxxxx látky (xxxxx).

X1. XXXXXXXXX XXXXXXX XXXXXXX

Zakázané je xxxxxxxxxxx:

X2. XXXXXXXX X XXXXXXXXX XXXXXXXXXX

X3. XXXXXX XXXXXX

Xxxxxxxxxxxxxx xxxxxxx xxxxx, xxxx, xxxxxxxx xxxxxxxx, xxxx xxxxxxxxxx xxxxxxx xxxx, xxxxx xxxx xxxxxxxxx xxxxxx xxxxxxxxx xxxxx, xx zakázané.

X6. XXXXXXXXXXX

Xxxxxxx xxxxxxxxxxx (xxxxxx obou xxxxxx xxxxxxxxxx xxxxxxxxx (X- a L-) xxxxxxx) xxxx zakázaná, x xxxxxxxx xxxxxxxx xxxxxxxxx x xxxxxxx xxxxxx xxxxxxxx užití x stimulancií zahrnutých xx Xxxxxxxxxxxxxx xxxxxxxx xxx xxx 2008.

Xxxxxxxxxxx zahrnují:

Adrafinil, xxxxxxxxx**, amfepramon, xxxxxxxxxxx, xxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxxxxx, bromantan, xxxxxxxxxx, xxxxxxxxxxxxxxxxx, efedrin****, xxxxxxxx, xxxxxxxxx, xxxxxxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxxx, fenetylin, xxxxxxxxxxx, xxxxxxxxxxx, fenkamin, xxxxxxxxxxx, xxxxxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxx, 4-xxxxxxxxxxxxxx (karfedon), xxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxxx, xxxxx***, klobenzorex, xxxxxx, xxxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxxxx (X-), xxxxxxxxxxxx****, xxxxxxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxxxxxxxxxxxxxx, methylfenidát, xxxxxxxx, xxxxxxxxx, niketamid, xxxxxxxxxxx, xxxxxxxxxxxxxx, xxxxxxxxx, xxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxxxxxxxxxx, xxxxxxx, xxxxxxxxxxx, p-methylamfetamin, xxxxxxxxx, propylhexedrin, selegilin, xxxxxxxxxx, xxxxxxxxx, tuaminoheptan x další xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx podobnými xxxxxxxxxxxx účinky.

Xxxxxxxxxxxx xxxxxxxxx výslovně xxxx xxxxxxxx v xxxxx xxxxxx xxxx xxxxxxxxxx xx specifickou xxxxx pouze, xxxxx Xxxxxxxxx prokáže, že xxxx xxxxxxxxx xxxxxxxxxx x xxxxxxx léčebných xxxxxxxxxxx xxxxxxxx xxxxxxxxx xxxxxxxx xxxxxxxxxxxxxxx xxxxxxxx, xxxx xx x xxx xxxxx xxxxxxxxxxxxxxx, xx xxxx xxxxxxx xxxxxxxx xxxx xxxxxxxxx xxxxx.

X7. XXXXXXXXX

Následující narkotika xxxx zakázaná:

Xxxxxxxxxxx, xxxxxxxxxxxxx, diamorfin(heroin), xxxxxxxx x xxxx deriváty, xxxxxxxxxxx, xxxxxxx, xxxxxx, xxxxxxxx, xxxxxxxxx, xxxxxxxxxx, xxxxxxx.

S8. XXXXXXXXXXX

Xxxxxxxxxxx (xxxx. xxxxx, xxxxxxxxx) xxxx xxxxxxxx.

S9. XXXXXXXXXXXXXXXXXXXX

Všechny xxxxxxxxxxxxxxxxxxxx xxxxxxxx xxxxxx, xxxxxxxx, xxxxxxxxxx xxxx xxxxxxxxxxxxx xxxxxxxx xxxx xxxxxxxx. Xxxxxx užití vyžaduje xxxxxxxxxxxxx xxxxxxx.

Xxxx xxxxxxx xxxxxxxx xxxxxxxx (xxxxxxxxxxxx, xx xxxxx xxxxxx, do okolí xxxxxx, xxxxxxxxxx, do xxxx) x inhalační xxxxxxxx vyžadují zkrácenou xxxxxxxxxxxxx výjimku x xxxxxxxx xxxx xxxxxxxxx.

Xxxxxxx xxxxxxxxx xxxxxxxx xx potíže xxxxx (xxxxxx iontoforézy/fonoforézy), xxxx, xxxxx, oční, potíže xxxxx řitního xxxxxx, xxxxxxxx xxx a xxxxx nejsou zakázané x nevyžadují žádnou xxxxx xxxxxxxxxxxx výjimky.

X1. XXXXXXX

Xxxxxxx (xxxxxx) xx xxxxxxxx pouze Xxx xxxxxxx x xxxxxxxxxxxxx xxxxxxxx. Xxxxxxx xx xxxx provádět xxxxxxxx xxxxxxxx a/nebo xxxxxxxx xxxx. Xxxxxxx xxxxxxx xxx xxxxxxxx xxxxxxxxxxx xxxxxxxx (xxxxxxxxxxxxx xxxxxxx) je pro xxxxxx federaci xxxxxxx x závorkách.

∙ Xxxxxxxxxxxx xxxxx (XXX) (0.10 g/l)

∙ Xxxxxx (XXX) (0.10 x/x)

∙ Xxxxxxx xxxxxx a xxxxxxxxxxxx (XXX) (0.20 g/l)

∙ Xxxxxxxxxxx (XXXX, XXX) (0.10 x/x)

∙ Xxxxxxx pětiboj (XXXX) jen xxx xxxxxxxxxx xx xxxxxxxx (0.10 x/x)

∙ Xxxxxxxxxxx xxxxx (XXX) (0.10 x/x)

∙ Xxxxx motorismus (XXX) (0.30 x/x)

∙ Xxxxxxx (XXX) (0.10 x/x)

X2. XXXX-XXXXXXXXX

Xxxxx xxxx jinak xxxxxx, xxxx-xxxxxxxxx xxxx xxxxxxxx xxxxx Xxx soutěži x xxxxxxxxxxxxx xxxxxxxx.

∙ Xxxxxxxxxxxx xxxxx (XXX)

∙ Xxxxxxxx (XXXX)

∙ Xxxx (XXXX)

∙ Xxxxx (XXX)

∙ Xxxxxxx (XXX)

∙ Xxxxxxxxxx (XXX)

∙ Xxxxxxxx (XXXX) - "match xxxx" - xxx xxxxxxxxxxx

∙ Kuželky (XXX)

∙ Xxxxxxx xxxxxx a xxxxxxxxxxxx (XXX)

∙ Lukostřelba (XXXX, XXX) (xxxxxxxx xxxx Mimo xxxxxx)

∙ Lyžování (XXX) - skoky na xxxxxx x akrobatické xxxxxxxx-xxxxx x U-rampa, x xxxxxxxxx X-xxxxx x "big xxx"

∙ Xxxxxxx xxxxxxx (XXXX) - xxx xxxxxxxxxx se xxxxxxxx

∙ Motocyklový xxxxx (XXX)

∙ Xxxxxxxx x obdobné xxxxxx (XXXX, XXX "xxxxx")

∙ Xxxxxxx (ISSF, XXX) (xxxxxxxx xxxx Xxxx xxxxxx)

∙ Xxxxx xxxxxxxxxx (UIM)

∙ Xxxxx (FILA)

Xxxx-xxxxxxxxx zahrnují xxxxxxxxxxx xxxxx:

Xxxxxxxxxx, xxxxxxxxxx, xxxxxxxx, xxxxxxxxx, xxxxxxxxxx, xxxxxxx, xxxxxxxxxx, esmolol, xxxxxxxxx, xxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxx, xxxxxxx, xxxxxxxxxx, pindolol, xxxxxxxxxxx, sotalol, xxxxxxx, xxx xx x xxxxxxxx pouze na xx

"Xxxxxxxxxx xxxxx"* xxxx xxxxxxxxxxx níže:

∙ Xxxxxxx Xxxx-2 xxxxxxxx x xxxxxxxx, xxxxx salbutamolu (volného xxxx xxxxxxxxxxx) při xxxxxxxx xxxxxx xxx 1000 ng/ml xxxx x clenbuterolu (zařazen xx xxxxxxx X 1.2 Xxxxxxx xxxxxxxxxx xxxxx);

∙ Xxxxxxxxxx xxxx-xxxxxxxxx, xxxxxxxxxx;

∙ Xxxxx, kropropamid, xxxxxxxxxx, xxxxxxx, xxxxxxxx, famprofazon, xxxxxxxxxxxxx, xxxxxxxxxx, isomethepten, xxxxxxxxxxxxxxx, meklofenoxát, x-xxxxxxxxxxxxxx, xxxxxxxxxxxx, niketamid, xxxxxxxxxxx, xxxxxxxxx, ortetamin, oxilofrin, xxxxxxxxxxxxxx, xxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxxxx x xxxxxxx xxxxxxx xxxxxxxxxxx xxxxxxxxx xxxxxxxx x oddíle X6, xxx xxxxx Xxxxxxxxx prokáže, že xxxxxxx xxxxxxxx popsané x xxxxxx X6;

∙ Xxxxxxxxxxx;

∙ Xxxxxxx Xxxxxxxxxxxxxxxxxxxx;

∙ Xxxxxxx;

∙ Všechny Xxxx-xxxxxxxxx.

*"V Xxxxxxx xxxxx xxx xxxxxxxxxxx xxxxxxxxxx látky, které xxxxxxxx xxxxxxxx neúmyslné xxxxxxxx xxxxxxxxxxxxxxx xxxxxxxx, xxxxxxx jsou xxxxxxxxx xxxxxxxx v běžných xxxxxxxxx xxxxxxxxxxx, xxxx x xxxxx xx xxxxx pravděpodobnost, že xxxxx xxxxxxx xxxxxxxx xxxx xxxxxxxxx činidla." Xxxxxxxx antidopingového pravidla xxxxxxxxxx xxxxxxxx látky xxxx znamenat xxxxxxx xxxxxx xx xxxxxxxxxxx, xx "...Sportovec může xxxxx xxxxxxxx, xx Xxxxxxx specifické xxxxx xxxxxx xxxxxxxxx ke xxxxxxx sportovního xxxxxx...".

Xxxxxx xxxxxxx x. 2/2008 Xx. x. x. nabyl xxxxxxxxx xxxx 31.1.2008.

Xxxxxx xxxxxxx x. 2/2008 Sb. m. x. xxx zrušen xxxxxxx xxxxxxxxx č. 8/2009 Sb. m. s. x účinností od 7.2.2009.

Xxxxx xxxxxxxxxxxx xxxxxxxx xxxxx xxxxxx xxxxxxxx xxxxxxxx x odkazech xxxx xxxxxxxxxxxxx, pokud xx xxxx netýká xxxxxxxxx xxxxx shora xxxxxxxxx xxxxxxxx xxxxxxxx.